Restless Leg syndrome. Restless legs syndrome
Conditions
Interventions
Intervention 1: Intervention group: KMT(Khosro Medisa Teb) Group Cannabidiol C2 drops containing 5 mg per ml of the liposomal form of cannabidiol will be used. At the beginning of the intervention, on
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Fulfill RLS criteria based on International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria 2014 Normal CBC, serum AST, ALT, Alp, BUN, Cr Serum ferritin level above 50 ng/ml Informed consent
Exclusion criteria
Exclusion criteria: Taking drugs that have a hepatic metabolism such as warfarin, anticonvulsants, antibiotics Taking dopamine antagonist drugs and other RLS treatment drugs during the past month History of drug abuses and impulse control disorders History of other sleep disorders History of other diseases related to the peripheral and central nervous systems History of cardiovascular, liver, kidney diseases and arrhythmia Pregnancy, lactation and patients using unsafe contraceptive methods Soy allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Restless Legs Syndrome Rating Scale. Timepoint: before intervention, 4 and 8 weeks after intervention. Method of measurement: Restless Legs Syndrome Rating Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactTara Khoeini
Iran University of Medical Sciences
Outcome results
None listed